A Novel Diagnostic Test for Irritable Bowel Syndrome

肠易激综合症的新型诊断测试

• 批准号: 6549592
• 负责人: DAVID A WAGNER
• 金额: $ 10万
• 依托单位: METABOLIC SOLUTIONS, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6549592
• 关键词: breath tests; carbon; clinical research; diagnosis design /evaluation; fructose; gastrointestinal disorder diagnosis; human subject; irritable bowel syndrome; malabsorption; radiotracer; stable isotope; stable isotope diagnosis

DESCRIPTION (provided by applicant): Irritable Bowel Syndrome (IBS) is a life altering disorder of the intestines that effects approximately 20 percent of the general population. There is no single diagnostic test for positive confirmation of IBS. Physicians arrive at an lBS diagnosis following a protocol that uses standard endoscopic tests to exclude structural or biochemical abnormalities, a physical examination and a symptom questionnaire. This inefficient process leads to an enormous use of healthcare resources estimated at 3.5 million office visits and 2.2 million prescriptions at a direct and indirect cost of $29 billion annually. Our objective is to develop an easy to use, low cost breath test to diagnosis lBS. The test developed by Metabolic Solutions (MSI) is based on the principle that lBS patients malabsorb fructose. In preliminary studies MSI has demonstrated a novel technology using a carbon 13 tracer and unlabeled fructose to identify individuals with lBS by whether or not they can absorb the administered fructose. This is the first test to assay fructose malabsorption directly from the small intestine and correlate it to the diagnosis of LBS. The proposed test will significantly reduce national health care expenditures because proper diagnosis will lead to fewer office visits, more prudent use of drugs and better general health and well-being for a large number of Americans.

描述（由申请人提供）：肠易激综合症 (IBS) 是一种改变生活的肠道疾病，影响着大约 20% 的普通人群。没有单一的诊断测试可以阳性确认 IBS。医生根据使用标准内窥镜检查排除结构或生化异常、体格检查和症状问卷的方案得出 IBS 诊断。这种低效流程导致医疗保健资源的大量使用，估计每年有 350 万次就诊和 220 万张处方，直接和间接成本达 290 亿美元。 我们的目标是开发一种易于使用、低成本的呼吸测试来诊断 IBS。 Metabolic Solutions (MSI) 开发的测试基于 IBS 患者果糖吸收不良的原理。在初步研究中，MSI 展示了一种新技术，使用碳 13 示踪剂和未标记的果糖，通过是否可以吸收所施用的果糖来识别患有 IBS 的个体。这是第一个直接检测小肠果糖吸收不良并将其与 LBS 诊断相关联的测试。 拟议的测试将显着减少国家医疗保健支出，因为正确的诊断将减少就诊次数，更谨慎地使用药物，并改善大量美国人的总体健康和福祉。